Drugs / CD22 CAR T cells
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06326008 | Mar → Jun 2026 overdue | B-cell acute lymphoblastic leukemia | Beijing GoBroad Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT04007978 | Aug 2019 → Jun 2022 | B-cell non-Hodgkin lymphoma, acute lymphoblastic leukemia | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 1 | NCT02721407 | Mar 2016 → Dec 2018 | diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma | Xinqiao Hospital of Chongqing | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06343090 | Apr 2024 → Dec 2042 expected | B-cell acute lymphoblastic leukemia | Beijing GoBroad Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD22 CAR T cells | “Patients receive CD22 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity.” NCT04007978 ↗3“To determine the safety of CD22.CAR-T cells in lymphoma patients refractory or resistent to anti-CD19:TCRz:CD28 CAR-T cells” NCT02721407 ↗ “Peripheral blood mononuclear cells for the production of CD19 CAR T cells and CD22 CAR T cells are collected from donors.” NCT06326008 ↗ |
| Action | Deplete | “kill tumor cells specifically” NCT04007978 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor (CAR)-modified T (CAR-T) cells” NCT02721407 ↗ |
| Target | CD22 | “Patients receive CD22 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity.” NCT04007978 ↗ |